Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
UK Startups and Innovation
14NOV

Ten raises took 75.2% of life sciences

2 min read
18:53UTC

The BioIndustry Association found that ten companies absorbed 75.2% of the £2.83 billion deployed into UK life sciences in the first half of 2026, leaving a median round of £600,000.

TechnologyDeveloping
Key takeaway

Ten companies took three quarters of the money while the median British life-sciences round reached £600,000.

The ten largest life-sciences raises took 75.2% of the £2.83 billion deployed into the sector in the first half of 2026, the BioIndustry Association (BIA), the trade body for British life sciences, reported on 10 September in a study written with the accountancy firm Frazier & Deeter⁠1. The median round across the same population came in at £600,000. The mean came in at £8.8 million.

A mean roughly fifteen times the median describes a market with a thin middle: a few enormous raises at the top, a long tail of very small ones, and little in between. The typical British life-sciences company raised enough to run one experiment. The British Business Bank measured the same concentration across the whole equity market last year, when artificial intelligence companies took a record 44% of smaller-business equity value. That market had a fashionable sector to explain it. This one does not, which points at round size rather than subject matter as the driver.

Go further down and the numbers shrink again. The Financial Conduct Authority (the FCA, the UK financial Conduct regulator) published feedback statement FS26/2 on 17 September, a review scoped to business lending of £25,000 or less to sole traders and small partnerships, the only small-business lending inside its consumer-credit perimeter. Within that perimeter it found that 60% of small businesses seeking finance in the past three years sought less than that ceiling⁠2. The median life-sciences round runs twenty-four times higher, and still sits on the same floor of British business finance that most companies stand on.

Deep Analysis

In plain English

The BioIndustry Association and the accountancy firm Frazier & Deeter looked at how £2.83bn of investment into British biotechnology and life sciences companies was shared out in the first half of 2026. Most of it went to a small number of companies. The ten biggest deals took three-quarters of all the money. Meanwhile, the typical company that raised money got only £0.6m, a small amount for biotech, where clinical trials are expensive. The gap between the typical deal and the average deal shows money is going to a few big winners rather than being spread evenly.

Deep Analysis
Root Causes

A £0.6m median round against an £8.8m mean is itself the signature of a barbell market: many small cheques at one end, a handful of large ones pulling the average far above the middle. That shape follows the retrenchment of generalist crossover investors from biotech after the 2022 downturn, which left fewer funds able or willing to write the mid-sized Series B and C cheques that used to sit between seed and late-stage rounds.

With that middle thinned out, the capital that remains concentrates in a small number of larger, more de-risked late-stage deals, which is exactly what the ten largest raises taking 75.2% of the £2.83bn total describes.

What could happen next?
  • Risk

    Companies raising near the GBP0.6m median face a harder path to the funding needed for clinical development, increasing the risk that promising early-stage UK life sciences work stalls before it reaches a fundable inflection point.

First Reported In

Update #15 · Nscale takes $103.4bn of contracts to NYSE

BioIndustry Association and Frazier & Deeter· 21 Sept 2026
Read original →
Different Perspectives
Association of Investment Companies (Richard Stone)
Association of Investment Companies (Richard Stone)
The trust industry body criticised the Budget for leaving Venture Capital Trust relief at 20%. It had lobbied for the 30% rate to return.
Tax Justice UK
Tax Justice UK
The campaign group opposed the 10% founders' rate as a giveaway to a small group of wealthy owners. It said the BADR cut should have gone further, to abolition.
techUK
techUK
The trade body set the new relief against the BADR cut, which halves the most a seller can save to £30,000. It says the Budget takes back with BADR part of what it gives founders.
Startup Coalition
Startup Coalition
The founder lobby group welcomed the Budget package for startups. It treats the new relief as the strongest government support for founders in years.
HM Treasury
HM Treasury
The Treasury created a 10% founders' relief on up to £10m of lifetime gains and expects about 600 people a year to use it. It says the relief rewards founders behind the UK's fastest-growing companies.
Abu Dhabi Investment Council
Abu Dhabi Investment Council
The Abu Dhabi Investment Council holds notes in Nscale's $3.36bn pre-IPO raise, beside Third Point, Apollo, Citadel and Nvidia. No British institution appears among the named holders of notes that convert into shares at Nscale's New York listing.

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Editorial standards.